Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors

Recruiting

• Conditions: Neuroendocrine Neoplasm; Cervical Lesion; Women; China; Cervical Cancer

• Registration Number: NCT06276309
• Lead Sponsor: Fujian Maternity and Child Health Hospital

Brief Summary

The clinical diagnosis and treatment data of 300 cases of cervical neuroendocrine tumors were collected, including age, preoperative biopsy pathology results, postoperative histopathological results, TCT results, and colposcopy biopsy pathology results. At the same time, paraffin tissue specimens (remaining specimens after pathological diagnosis) from 100 cases of cervical neuroendocrine tumors from multiple centers across the country were collected to establish a cervical neuroendocrine tumor data follow-up database. Protein concentration and omics analysis were performed on the data results, to evaluate the molecular characteristics and prognosis of cervical neuroendocrine tumor proteins, and to preliminarily explore its clinical application value.

Detailed Description

1. The clinical diagnosis and treatment data of 300 cases of cervical neuroendocrine tumors were used for prognostic analysis.

(1) The diagnosis and treatment information of cervical neuroendocrine carcinoma in multiple hospitals was collected, including clinical and medical data such as age, preoperative HPV genotyping, preoperative biopsy pathological results, postoperative histopathological results, FIGO staging, prognosis and survival information, and follow-up of patients.

2. Protein and other omics analysis was performed on paraffin tissues of 100 cases of cervical neuroendocrine tumors Paraffin samples collected from 100 cases of cervical neuroendocrine tumors were identified, processed and segmtioned, and protein concentration and proteome were determined to establish the molecular characteristics and prognostic targets of cervical neuroendocrine tumors.

Study Timeline

• Status Verified: 2024-02
• Study Start: 2024-02-01
• Study First Submitted: 2024-02-07
• Study First Submitted QC: 2024-02-21
• Last Update Submitted: 2024-02-21
• Study First Posted: 2024-02-23
• Last Update Posted: 2024-02-23
• Primary Completion: 2024-06-30
• Study Completion: 2024-06-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 300

Inclusion Criteria

1. Patients diagnosed with cervical neuroendocrine carcinoma by histopathology
2. Clinical data were complete

Exclusion Criteria

1. Patients who are not being treated in our hospital
2. Patients with lack of follow-up data, unable to obtain survival information
3. Patients call to refuse to participate in this project
4. The quality of paraffin specimens can not meet the requirements of proteome concentration determination

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Disease-free survival	Among patients with cervical neuroendocrine carcinoma, the disease-free survival within 3 years following surgery	3-year disease-free survival for cervical neuroendocrine carcinoma
mortality rate	Among patients with cervical neuroendocrine carcinoma, the mortality rate within 3 years following surgery	3-year mortality rate for cervical neuroendocrine carcinoma

Trial Locations

Locations (9)

Xiangya Hospital, Central South University; 🇨🇳 Changsha, Hunan, China

Jiangxi maternal and Child Health Hospital; 🇨🇳 Nanchang, Jiangxi, China

Fujian Maternity and Child Health Hospital; 🇨🇳 Fuzhou, Fujian, China

Fujian Provincial Hospital; 🇨🇳 Fuzhou, Fujian, China

The Second Affiliated Hospital of Fujian Medical University; 🇨🇳 Quanzhou, Fujian, China

Zhangzhou affiliated Hospital of Fujian Medical University; 🇨🇳 Zhangzhou, Fujian, China

Maternal and Child Health Hospital of Hubei Province; 🇨🇳 Wuhan, Hubei, China

Putian City first Hospital; 🇨🇳 Putian, Fujian, China

Ningde Mindong Hospital; 🇨🇳 Ningde, Fujian, China